301211.SHE Hubei Biocause Heilen Pharmaceutical Co. Ltd.
- Market cap
- CNY 4.31B
- P/E
- 85.9x
- P/B
- 1.88x
- ROE
- 2.3%
- Dividend yield
- 1.67%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301211.SHE undervalued?
Graham number301211.SHE trades 168.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hubei Biocause Heilen Pharmaceutical Co. Ltd. fundamental analysis
No fundamental analysis for Hubei Biocause Heilen Pharmaceutical Co. Ltd. yet.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardio…
Full company profileHubei Biocause Heilen Pharmaceutical Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 366M | 517M | 660M | 593M | 541M | 515M | 663M | 446M | 453M | 473M |
| Gross Profit | 101M | 222M | 341M | 294M | 182M | 145M | 265M | 128M | 100M | 110M |
| Operating Income | 27.0M | 107M | 218M | 199M | 139M | 149M | 205M | 101M | 7.41M | 24.0M |
| EBITDA | 45.5M | 130M | 243M | 219M | 159M | 168M | 224M | 125M | 84.8M | 57.2M |
| Net Income | 10.3M | 47.7M | 100M | 168M | 122M | 126M | 176M | 91.5M | 34.9M | 52.9M |
| EPS | 0.03 | 0.16 | 0.32 | 0.53 | 0.39 | 0.30 | 0.42 | 0.22 | 0.08 | 0.13 |
| Balance Sheet | ||||||||||
| Total Assets | 535M | 640M | 746M | 803M | 2.33B | 2.50B | 2.55B | 2.49B | 2.40B | 2.39B |
| Total Liabilities | 227M | 240M | 257M | 103M | 108M | 221M | 190M | 179M | 129M | 104M |
| Shareholders' Equity | 238M | 286M | 488M | 700M | 2.22B | 2.28B | 2.36B | 2.31B | 2.27B | 2.29B |
| Cash & Short-term Investments | 48.8M | 61.6M | 362M | 345M | 1.86B | 1.96B | 1.82B | 1.64B | 448M | 386M |
| Total Debt | 102M | 117M | 20.0M | 7.26M | 30.3M | 7.40M | 5.15M | 19.2M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -65.4M | 76.2M | 372M | 122M | 124M | 251M | 137M | 96.1M | 7.55M | - |
| Capital Expenditure | 13.1M | 25.1M | 32.3M | 13.4M | 21.1M | 76.0M | 187M | 164M | 52.3M | 72.4M |
| Free Cash Flow | -78.6M | 51.1M | 340M | 108M | 103M | 175M | -49.5M | -68.4M | -44.8M | -45.5M |
| Ratios | ||||||||||
| ROE | 4.3% | 16.7% | 20.5% | 24.0% | 5.5% | 5.5% | 7.5% | 4.0% | 1.5% | 2.3% |
| ROA | 1.9% | 7.5% | 13.5% | 20.9% | 5.2% | 5.0% | 6.9% | 3.7% | 1.5% | 2.2% |
| Net Profit Margin | 2.8% | 9.2% | 15.2% | 28.3% | 22.5% | 24.4% | 26.6% | 20.5% | 7.7% | 11.2% |
| Debt to Equity | 0.43x | 0.41x | 0.04x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. dividends
- Dividend yield
- 1.67%
- Forward dividend
- 0.06 CNY
- Payout ratio
- 206.2%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 72.0M | 0.17 | 206.2% |
| 2024 | CNY 138M | 0.33 | 151.0% |
| 2023 | CNY 96.0M | 0.23 | 54.5% |
| 2022 | CNY 72.0M | 0.17 | 57.2% |
| 2021 | - | - | - |
| 2020 | CNY 2.28M | 0.01 | 1.4% |
| 2019 | CNY 3.92M | 0.01 | 3.9% |
| 2018 | 6.45M | 0.02 | 13.5% |
| 2017 | 2.77M | 0.01 | 27.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.45:1 on Aug 27, 2025.
Who owns Hubei Biocause Heilen Pharmaceutical Co. Ltd.
- Insiders 73.58%
- Institutions 0.10%
- Public & others 26.32%
- Shares outstanding 418M
- Free float 185M
Hubei Biocause Heilen Pharmaceutical Co. Ltd. company profile
- Company name
- Hubei Biocause Heilen Pharmaceutical Co. Ltd.
- Ticker
- 301211.SHE
- ISIN
- CNE100005782
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 952
- Fiscal year end
- December
- Address
- No. 122 Yangwan Road, Jingmen, China, 448000
- Phone
- 86 27 6565 1730
- Website
- biocause.com
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granisetron hydrochloride; and preparation products, such as cardiovascular preparations torsemide tablets and non-steroidal anti-inflammatory preparations ibuprofen granules, and other preparations. In addition, it offers non-anti-inflammatory APIs, cardiovascular, anti-tumor, and anticholinergic APIs and intermediates; antipyretic and analgesic, cardiovascular and anti-infective preparations; and chemicals and formulations. Hubei Biocause Heilen Pharmaceutical Co., Ltd. was founded in 1995 and is based in Jingmen, China.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. management
10- Mr. Qun LiangGeneral Manager · born 1971
- Mr. Ting Hao YiFinancial Director · born 1973
- Ms. Chunli YangExecutive VP & Director · born 1970
- Mr. Xuyong DaiChief Engineer · born 1979
- Mr. Jian GaoBoard Secretary · born 1977
- Mr. Zhenghua HuangDeputy General Manager · born 1972
- Mr. Weihua ZhuDeputy General Manager · born 1967
- Ms. Kuili ZhangDeputy General Manager · born 1976
- Ms. Qianqian GuanDeputy General Manager · born 1983
- Chun Hua QuanAccounting Supervisor